Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
about
Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?Is GLP-1 a hormone: Whether and When?Pancreatic α-Cell Dysfunction in Type 2 Diabetes: Old Kids on the BlockPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseIndirect effects of glucagon-like peptide-1 receptor agonist exendin-4 on the peripheral circadian clocks in miceGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesComparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes.Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusionEffect of endogenous GLP-1 on insulin secretion in type 2 diabetes.Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans.Proglucagon-derived peptides: mechanisms of action and therapeutic potential.Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes.Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humansThe role of gut hormones in glucose homeostasisEffects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.Gut peptides in the treatment of diabetes mellitus.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell functionRegulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides.The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes.Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetesGLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channelGlucagon-like peptide 1 (GLP-1) and metabolic diseases.Comparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and MechanismsPostprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Exenatide can reduce glucose independent of islet hormones or gastric emptying.Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects.Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestionContributions of fat and protein to the incretin effect of a mixed meal.Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue.Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.Add-on therapies to metformin for type 2 diabetes.The role of dysregulated glucagon secretion in type 2 diabetes.Update on incretin hormones.Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus.Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
P2860
Q26744254-89CC98D5-82DD-4FE3-A269-3C5E52ABBAA6Q26749196-E0CFFE56-61FA-49C1-BD5F-ABE8AA9BF443Q26825393-2229D97F-482F-44B9-A5E5-BAD48F212DBBQ27027920-65DFD81E-946C-4FF5-A8C4-CAA28BE323EFQ27301386-40E16A63-C5C1-4153-B09B-CCC92D1827A9Q28067465-B9B54568-590A-4B03-82FF-687316804ABFQ33585686-BD437ABC-7185-4DE7-9530-0EAB7138C7A1Q33829210-198C8AEA-B827-4C43-87FB-41C165BEDA48Q33869732-DE58A815-792B-4454-A0F8-203BCE2D8A53Q34225924-644BEBA9-A7C2-4080-95C2-E29DE8741F24Q34452524-49BBDE53-3C4D-477D-B599-9AEC323F4276Q34648201-89D97964-D494-487C-9A1A-FF61122FB435Q35049845-85C93955-86BC-4CF7-8898-575E8EA1F6C7Q35110843-38F3C9F3-6053-456E-A6FD-6C9990E1285AQ35179981-4AE50746-B101-4C5B-847D-96E55C403726Q35251016-BECC7073-3C07-485F-9432-24C54CC79958Q35360292-6D4BAA07-BCCA-4641-AEF3-7253ACC46D85Q35688209-4EB17719-DA48-40E1-84DE-0611A826AF4BQ35772029-5127FDA1-DC19-45E7-B40E-831C7E349F12Q35797043-20A2F158-BE36-4212-8B55-0A82007D332EQ36049852-17572F70-D1B5-4005-A663-0EE318853D0EQ36182540-D8329AD1-A066-435A-A581-2C287FA204B3Q36240979-277CC11B-CAB0-4FF3-9682-D6357D9B9F31Q36249759-8E9EB633-F1D7-4DA3-8DCB-551BF7C7CA7BQ36309183-27BC7A1E-9A14-430F-82D1-EE80FFE47C10Q36479829-94B5038D-1E49-4154-B343-CC8351FFF052Q36520647-A6271887-C759-4F6C-98B3-FB58FB3AC21CQ36846123-372A8762-998D-4960-87B0-3179010AF83CQ37031078-22CF5963-38DD-4A8D-BAA9-0F1999BF9DDAQ37061286-CDA79C2B-FD98-4E7B-8A54-3AC1A35F9B8DQ37092070-D3676111-387D-4C83-B9C4-165953262CBFQ37110621-2F97F9D8-8EF9-4AD6-A24D-3F35926C8083Q37316259-A6050DA3-2DC3-4546-8374-EB0081CEB2D3Q37579230-9AF7E6B5-F673-4328-B590-3FE567C68CC3Q37670181-089310FE-0C41-4851-BDF2-3318E6E47CB7Q37818234-70A307F8-DFE9-4CBC-BD3C-622EFA69379CQ37913523-C1BF5F4F-1859-46E3-B338-133BAB3FA9B4Q38006504-B4995B3D-D811-46BE-9B24-A4B66F8013CBQ38024321-ECAACA1D-04D7-4A0E-8F8F-EDF08531AB84Q38122004-ECFA66CD-5453-4BDA-838E-3AABCDD420A2
P2860
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Exendin
@nl
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
@en
type
label
Exendin
@nl
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
@en
prefLabel
Exendin
@nl
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
@en
P2093
P2860
P356
P1476
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
@en
P2093
P2860
P304
P356
10.1172/JCI1349
P407
P577
1998-04-01T00:00:00Z